203 related articles for article (PubMed ID: 31896782)
21. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
[TBL] [Abstract][Full Text] [Related]
22. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
[TBL] [Abstract][Full Text] [Related]
23. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
24. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
27. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
28. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
29. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N; Terzer T; Sträng E; Dolnik A; Cocciardi S; Panina E; Corbacioglu A; Herzig J; Weber D; Schrade A; Götze K; Schröder T; Lübbert M; Wellnitz D; Koller E; Schlenk RF; Gaidzik VI; Paschka P; Rücker FG; Heuser M; Thol F; Ganser A; Benner A; Döhner H; Bullinger L; Döhner K
Blood Adv; 2020 Dec; 4(24):6342-6352. PubMed ID: 33351131
[TBL] [Abstract][Full Text] [Related]
30. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
31. Therapy-related core binding factor acute myeloid leukemia.
George B; Yohannan B; Mohlere V; Gonzalez A
Int J Hematol Oncol; 2023 Feb; 12(1):IJH43. PubMed ID: 36874378
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
[TBL] [Abstract][Full Text] [Related]
33. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
34. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.
Illmer T; Schaich M; Ehninger G; Thiede C;
Haematologica; 2007 Jan; 92(1):137-8. PubMed ID: 17229652
[TBL] [Abstract][Full Text] [Related]
36. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
37. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Chen W; Xie H; Wang H; Chen L; Sun Y; Chen Z; Li Q
PLoS One; 2016; 11(1):e0146614. PubMed ID: 26771376
[TBL] [Abstract][Full Text] [Related]
39. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Panigrahi C; Tikare N; Das PK; Padhi S
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
[TBL] [Abstract][Full Text] [Related]
40. Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia.
Hu X; Cai H; Zheng L; Luo Y; Zhou J; Hui Y; Dai Z; Lin H; Li D; Xiao Y; Huang L; Zhou J
Cancer Med; 2020 Jul; 9(14):4941-4948. PubMed ID: 32419364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
